ASBP — Aspire Biopharma Holdings Share Price
Last trade - 00:00- $6.92m
- $2.56m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | 1.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 200.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -152.42% | ||
| Return on Equity | n/a | ||
| Operating Margin | -17491.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +120.78 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. The Company is a developer of multi-faceted patent-pending drug delivery technology. It is engaged in developing and marketing the disruptive technology for novel sublingual delivery mechanisms for known drugs. Its patent pending delivery system includes components formulated to allow sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract. Its delivery technology is focused on different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. Its Sublingual Aspirin Product addresses cardiology emergencies and pain management. Its other products include Melatonin, Vitamins, Erectile Dysfunction Medication, Caffeine Products, and Other Products, which includes anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- February 17th, 2025
- Public Since
- February 18th, 2022
- No. of Shareholders
- 396
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,295,234
- Address
- 23150 Fashion Drive, Suite 232, ESTERO, 33928
- Web
- Phone
- +1 3026587581
- Auditors
- Turner, Stone & Company
Upcoming Events for ASBP
Similar to ASBP
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
FAQ
As of Today at 19:22 UTC, shares in Aspire Biopharma Holdings are trading at $5.34. This share price information is delayed by 15 minutes.
Shares in Aspire Biopharma Holdings last closed at $5.34 and the price had moved by -98.69% over the past 365 days. In terms of relative price strength the Aspire Biopharma Holdings share price has underperformed the S&P500 Index by -98.94% over the past year.
There is no consensus recommendation for this security.
Find out moreAspire Biopharma Holdings does not currently pay a dividend.
Aspire Biopharma Holdings does not currently pay a dividend.
Aspire Biopharma Holdings does not currently pay a dividend.
To buy shares in Aspire Biopharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.34, shares in Aspire Biopharma Holdings had a market capitalisation of $6.92m.
Here are the trading details for Aspire Biopharma Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ASBP
Based on an overall assessment of its quality, value and momentum Aspire Biopharma Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aspire Biopharma Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -95.49%.
As of the last closing price of $5.34, shares in Aspire Biopharma Holdings were trading -97.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aspire Biopharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Aspire Biopharma Holdings' directors